Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 773

1.

Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.

Visser EP, Philippens ME, Kienhorst L, Kaanders JH, Corstens FH, de Geus-Oei LF, Oyen WJ.

J Nucl Med. 2008 Jun;49(6):892-8. doi: 10.2967/jnumed.107.049585. Epub 2008 May 15.

2.

Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic 18F Fluorodeoxyglucose PET.

Meijer TWH, de Geus-Oei LF, Visser EP, Oyen WJG, Looijen-Salamon MG, Visvikis D, Verhagen AFTM, Bussink J, Vriens D.

Radiology. 2017 May;283(2):547-559. doi: 10.1148/radiol.2016160329. Epub 2016 Nov 15.

PMID:
27846378
3.

Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.

Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, Cachin F, Berriolo-Riedinger A, Olivier P, Kolesnikov-Gauthier H, Blagosklonov O, Bridji B, Devillers A, Collombier L, Courbon F, Gremillet E, Houzard C, Caignon JM, Roux J, Aide N, Brenot-Rossi I, Doyeux K, Dubray B, Vera P.

J Nucl Med. 2013 Sep;54(9):1543-50. doi: 10.2967/jnumed.112.118083. Epub 2013 Aug 5.

4.

The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.

Ashamalla H, Rafla S, Parikh K, Mokhtar B, Goswami G, Kambam S, Abdel-Dayem H, Guirguis A, Ross P, Evola A.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1016-23. Epub 2005 Jun 24.

PMID:
15979817
5.

Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.

Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, Kirsch CM.

J Nucl Med. 2005 Aug;46(8):1342-8.

6.

Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.

Hong R, Halama J, Bova D, Sethi A, Emami B.

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):720-6.

PMID:
17293230
7.

Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.

Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, Boellaard R.

J Nucl Med. 2016 Sep;57(9):1343-9. doi: 10.2967/jnumed.115.170225. Epub 2016 Apr 21.

PMID:
27103020
8.

Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.

Heusch P, Buchbender C, Köhler J, Nensa F, Beiderwellen K, Kühl H, Lanzman RS, Wittsack HJ, Gomez B, Gauler T, Schuler M, Forsting M, Bockisch A, Antoch G, Heusner TA.

Rofo. 2013 Nov;185(11):1056-62. doi: 10.1055/s-0033-1350110. Epub 2013 Jul 16.

9.

FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes.

Devic S, Mohammed H, Tomic N, Aldelaijan S, De Blois F, Seuntjens J, Lehnert S, Faria S.

Br J Radiol. 2016 Jun;89(1062):20150388. doi: 10.1259/bjr.20150388. Epub 2016 Mar 23.

PMID:
27007269
10.

Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).

Edet-Sanson A, Dubray B, Doyeux K, Back A, Hapdey S, Modzelewski R, Bohn P, Gardin I, Vera P.

Radiother Oncol. 2012 Feb;102(2):251-7. doi: 10.1016/j.radonc.2011.07.023. Epub 2011 Aug 30.

PMID:
21885145
11.

Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.

Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y, Ohkawa M.

Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1610-6. Epub 2007 May 26.

PMID:
17530250
12.

Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.

Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H, Boellaard R.

J Nucl Med. 2010 Dec;51(12):1870-7. doi: 10.2967/jnumed.110.077255. Epub 2010 Nov 15.

13.

Defining a radiotherapy target with positron emission tomography.

Black QC, Grills IS, Kestin LL, Wong CY, Wong JW, Martinez AA, Yan D.

Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1272-82.

PMID:
15519800
14.

Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.

Dong X, Wu P, Sun X, Li W, Wan H, Yu J, Xing L.

J Med Imaging Radiat Oncol. 2015 Jun;59(3):338-45. doi: 10.1111/1754-9485.12289. Epub 2015 Feb 23.

PMID:
25708154
15.

Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.

Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A, Ohnuki T, Nishikawa T, Kusakabe K.

J Nucl Med. 2006 Mar;47(3):426-31.

16.

Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.

Conrad GR, Sinha P.

Nucl Med Commun. 2003 Nov;24(11):1129-37.

PMID:
14569166
17.

Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.

Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.

Biomed Mater Eng. 2014;24(6):3091-103. doi: 10.3233/BME-141131.

PMID:
25227018
18.

Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.

Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Holstein A, Dietlein M, Wolf J, Kobe C.

J Nucl Med. 2011 Dec;52(12):1871-7. doi: 10.2967/jnumed.111.094458. Epub 2011 Nov 7.

19.

A prospective analysis of ¹⁸F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features.

Calcagni ML, Mattoli MV, Blasi MA, Petrone G, Sammarco MG, Indovina L, Mulè A, Rufini V, Giordano A.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1682-91. doi: 10.1007/s00259-013-2488-6. Epub 2013 Jul 4.

PMID:
23824464
20.

Defining target volumes for stereotactic ablative radiotherapy of early-stage lung tumours: a comparison of three-dimensional 18F-fluorodeoxyglucose positron emission tomography and four-dimensional computed tomography.

Hanna GG, van Sörnsen de Koste JR, Dahele MR, Carson KJ, Haasbeek CJ, Migchielsen R, Hounsell AR, Senan S.

Clin Oncol (R Coll Radiol). 2012 Aug;24(6):e71-80. doi: 10.1016/j.clon.2012.03.002. Epub 2012 Mar 24.

PMID:
22445302

Supplemental Content

Support Center